ClinicalTrials.gg
CompletedNCT04080726Updated Nov 30, 2020

Efficacy and Safety of HIP1601 Capsule

A Phase 3 interventional study of HIP1601 and HGP1705 in Erosive Gastroesophageal Reflux Disease, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-11-30.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2018, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.

Enrollment
28th of 66
213 · median 125
Started
2018
with 1 other
Phase 3
15 of 67
none open now
Registered
61st of 67
by date

Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 28th largest by enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2018, is one of 15 in phase 3, and was the 61st registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing esomeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with erosive gastroesphageal reflux disease.

03

Conditions studied

  • Erosive Gastroesophageal Reflux Disease
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19≤ age ≤ 75
  • Esophago-Gastro-Duodenoscopy LA classification ≥ grade A
  • Patients experienced heartburn or acid regurgitation within 7 days of screening day
  • Patients understood the consents and purpose of this trial and signed consent form

Exclusion criteria

Exclusion Criteria:

  • Has in the upper gastrointestinal tract, digestive ulcer, bleeding disorder or signs of gastrointestinal bleeding
  • Has a severe liver disorder(at screening day, or ALT level exceeds 3 times more than normal upper range)
  • Has a renal failure(at screening day, eGFP ≤ 59 mL/min/1.73m2 or Serum creatinine >2.0mg/dL)
  • Uncontrolled diabetes mellitus
  • Before screening EGD, a patient who has taken H2-receptor antagonist or PPI within 2 weeks
  • Before screening EGD, a patient who has taken drugs containing following list within 1 weeks : warfarin, anticholinergics for spasmolytic GI, antineoplastic agents, salicylates(except 100mg a day for prevention of cardiovascular disease), , propulsives, sucralfate, NSAIDs, other antacids(e.g. antacids of prostaglandin analogs, antacids of aluminum/magnesium)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    HIP1601+HGP1705 Placebo

    HIP1601+HGP1705 Placebo for 4weeks. if not fully cured, take HIP1601+HGP1705 Placebo for addtional 4weeks

    Drug: HIP1601 · Drug: HGP1705 Placebo

  • Experimental
    HGP1705+HIP1601 Placebo

    HGP1705+HIP1601 Placebo for 4weeks. if not fully cured, take HGP1705+HIP1601 Placebo for addtional 4weeks

    Drug: HGP1705 · Drug: HIP1601 Placebo

Interventions

  • Oral esomeprazole

    Also known as: esomeprazole

  • Oral Nexium Tab

    Also known as: Nexium Tab

  • DrugHIP1601 Placebo

    Oral Placebo

  • DrugHGP1705 Placebo

    Oral Placebo

06

What researchers measure

Primary outcomes

  1. Complete healing rate

    percentage of subjects whose erosion is completely cured

    Time frame: at 4 weeks or 8 weeks

Secondary outcomes

  1. Complete healing rate

    percentage of subjects whose erosion is completely cured

    Time frame: at 4 weeks

  2. Complete resolution rate of each symptom in GERD

    Time frame: at 4,8 weeks

  3. Proportion of heartburn-free days, acid regurgitation-free days

    Time frame: at 1, 2, 4, 8 weeks

  4. Proportion of heartburn-free nights, acid regurgitation-free nights

    Time frame: at 1, 2, 4, 8 weeks

  5. Time to sustained resolution heartburn, acid regurgitation

    Time frame: at 4 weeks or 8 weeks

  6. Time to sustained resolution of nocturnal heartburn, nocturnal acid regurgitation

    Time frame: at 4 weeks or 8 weeks

  7. Total number of use of relief drugs and average usage per day

    Time frame: at 4 weeks or 8 weeks

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Dec 2019, 13 months.

Of 21 phase 3 interventional studies under Gastroesophageal Reflux, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 49. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2019
First posted
Sep 6, 2019
StartActual
Oct 25, 2018
Primary completionActual
Dec 3, 2019
CompletionActual
Dec 3, 2019
Last update
Nov 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04080726
Responsible party
Sponsor
First posted
Sep 6, 2019
Start date
Oct 25, 2018
Primary completion
Dec 3, 2019
Completion
Dec 3, 2019
Last update
Nov 30, 2020

Study contacts

Hunyong Jung, MD, Ph.D.
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Esomeprazole · HGP1705

Start the discussion